Australia's Antisense jumps on upbeat EMA feedback for DMD treatment

Percheron Therapeutics

30/09/2021 05:02

** Shares of the biotechnology firm  ANP.AX  rise as much as
8.9% to A$0.215, their best day since Sep 20
    ** Co gets positive feedback from the European Medicines
Agency on its paediatric investigation plan for development of
ATL1102 to treat Duchenne muscular dystrophy (DMD)  urn:newsml:reuters.com:*:nGLF9hQWHy
    ** DMD is a genetic disorder which results in a progressive
decline in muscle strength
    ** ANP says site evaluation and document preparation for
clinical trial applications are underway
    ** Co had earlier applied to the U.S. Food and Drug
Administration for fast track designation and received a
positive feedback on study design parameters for ATL1102
 urn:newsml:reuters.com:*:nL3N2O40WQ
    ** More than 520,000 shares have changed hands vs 30-day
average of about 900,000 shares
    ** Stock up 51.9% YTD, as of last close

 (Reporting by Jaskiran Singh in Bengaluru)
 ((jaskiran.singh@thomsonreuters.com))